See more : Gladstone Land Corporation (LANDM) Income Statement Analysis – Financial Results
Complete financial analysis of AFC-HD AMS Life Science Co., Ltd. (2927.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AFC-HD AMS Life Science Co., Ltd., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- Zevia PBC (ZVIA) Income Statement Analysis – Financial Results
- Southern Cross Media Group Limited (SXL.AX) Income Statement Analysis – Financial Results
- Enbridge Inc. (ENBBF) Income Statement Analysis – Financial Results
- Fortive Corporation (FTV) Income Statement Analysis – Financial Results
- T.W. Christian, Inc (TWCI) Income Statement Analysis – Financial Results
AFC-HD AMS Life Science Co., Ltd. (2927.T)
About AFC-HD AMS Life Science Co., Ltd.
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and supplements. It plans, researches, develops, and processes, as well as completes dietary supplement and cosmetics. The company offers health foods in various forms, such as tablets, soft and hard capsules, granules, soft drinks, and jellies. Its cosmetic products include facial cleansing, lotions, milky lotions, makeup oils, cleansing creams, and liquid cosmetics.. The company also wholesales dietary supplements and cosmetics; collects health-related information; plans and produces TV commercials, TV shopping channels, and video packages; publishes health magazines; and operates day and night care center under the Hello House name, and prep school under the Hello Gakuen name. In addition, it sells dietary supplements and cosmetics through mail orders; operates Internet shops; offers Kanpou, a general practitioner medicine for medical care; and produces and sells health care merchandise. The company operates in Japan, rest of Asia, and internationally. The company was formerly known as AMS Life Science Co., Ltd. and changed its name to AFC-HD AMS Life Science Co., Ltd. in March 2010. AFC-HD AMS Life Science Co., Ltd. was founded in 1969 and is headquartered in Shizuoka, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.19B | 25.58B | 23.00B | 22.37B | 15.82B | 16.25B | 15.80B | 15.14B | 14.63B | 14.42B | 13.73B | 14.37B | 14.79B | 14.65B | 14.45B | 12.81B | 10.22B |
| Cost of Revenue | 19.69B | 16.26B | 14.42B | 15.50B | 11.26B | 11.73B | 11.20B | 10.53B | 10.24B | 10.15B | 9.62B | 9.93B | 10.05B | 9.27B | 9.25B | 7.90B | 6.11B |
| Gross Profit | 10.49B | 9.32B | 8.58B | 6.87B | 4.55B | 4.52B | 4.59B | 4.61B | 4.39B | 4.26B | 4.11B | 4.44B | 4.74B | 5.39B | 5.20B | 4.92B | 4.11B |
| Gross Profit Ratio | 34.76% | 36.45% | 37.30% | 30.69% | 28.79% | 27.82% | 29.08% | 30.43% | 30.00% | 29.56% | 29.95% | 30.88% | 32.05% | 36.76% | 36.01% | 38.37% | 40.25% |
| Research & Development | 0.00 | 145.06M | 153.03M | 163.70M | 166.36M | 156.62M | 139.19M | 116.11M | 110.14M | 108.00M | 105.00M | 82.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 6.78B | 6.53B | 3.91B | 2.90B | 2.88B | 2.84B | 2.88B | 2.90B | 2.85B | 3.00B | 2.98B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 748.00M | 736.00M | 504.00M | 438.00M | 505.00M | 586.00M | 539.00M | 487.00M | 428.00M | 517.00M | 500.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 7.38B | 7.26B | 4.42B | 3.34B | 3.38B | 3.43B | 3.42B | 3.39B | 3.27B | 3.52B | 3.48B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 8.58B | 16.00M | 7.57B | 4.62B | 3.46B | 3.54B | 12.64M | 36.46M | 192.00K | 35.83M | 53.91M | 42.75M | 105.06M | 54.50M | 92.67M | 56.43M | 103.92M |
| Operating Expenses | 8.58B | 7.69B | 7.57B | 4.62B | 3.46B | 3.54B | 3.57B | 3.54B | 3.50B | 3.31B | 3.55B | 3.53B | 4.03B | 4.36B | 4.44B | 4.18B | 3.27B |
| Cost & Expenses | 28.27B | 23.94B | 21.99B | 20.12B | 14.73B | 15.27B | 14.77B | 14.07B | 13.74B | 13.46B | 13.16B | 13.46B | 14.08B | 13.63B | 13.68B | 12.08B | 9.37B |
| Interest Income | 2.46M | 4.19M | 4.06M | 3.47M | 3.35M | 2.17M | 68.00K | 68.00K | 279.00K | 443.00K | 1.06M | 465.00K | 437.00K | 439.00K | 1.60M | 2.17M | 1.73M |
| Interest Expense | 101.27M | 57.56M | 57.59M | 50.04M | 32.92M | 36.52M | 57.84M | 65.37M | 78.89M | 95.36M | 111.74M | 127.04M | 142.78M | 83.55M | 78.54M | 81.57M | 54.03M |
| Depreciation & Amortization | 1.09B | 984.00M | 1.01B | 649.88M | 509.95M | 473.79M | 437.12M | 384.30M | 397.04M | 439.42M | 508.02M | 597.73M | 730.03M | 364.08M | 430.53M | 407.22M | 277.22M |
| EBITDA | 3.10B | 2.59B | 2.30B | 2.86B | 1.55B | 1.60B | 1.48B | 1.09B | 1.23B | 1.49B | 1.11B | 1.70B | 1.86B | 1.38B | 1.24B | 1.19B | 1.14B |
| EBITDA Ratio | 10.26% | 10.12% | 10.40% | 12.80% | 10.36% | 9.24% | 9.26% | 9.84% | 8.80% | 9.90% | 8.21% | 10.74% | 10.45% | 9.85% | 8.95% | 9.25% | 12.06% |
| Operating Income | 1.92B | 1.64B | 1.39B | 2.25B | 1.09B | 981.27M | 1.02B | 1.07B | 890.84M | 951.19M | 564.53M | 902.15M | 711.19M | 1.02B | 767.72M | 737.69M | 849.54M |
| Operating Income Ratio | 6.35% | 6.40% | 6.03% | 10.04% | 6.91% | 6.04% | 6.48% | 7.06% | 6.09% | 6.60% | 4.11% | 6.28% | 4.81% | 6.99% | 5.31% | 5.76% | 8.31% |
| Total Other Income/Expenses | -5.39M | -90.32M | -150.35M | -87.43M | -89.34M | 109.75M | -37.83M | -431.95M | -135.77M | 4.58M | -70.28M | 74.62M | 255.63M | -95.76M | -83.47M | -313.45M | -43.75M |
| Income Before Tax | 1.91B | 1.55B | 1.24B | 2.16B | 1.00B | 1.09B | 985.65M | 637.30M | 755.07M | 955.77M | 494.25M | 976.77M | 966.82M | 928.91M | 684.26M | 424.24M | 805.78M |
| Income Before Tax Ratio | 6.33% | 6.04% | 5.37% | 9.65% | 6.35% | 6.71% | 6.24% | 4.21% | 5.16% | 6.63% | 3.60% | 6.80% | 6.53% | 6.34% | 4.74% | 3.31% | 7.88% |
| Income Tax Expense | 665.40M | 439.36M | 497.92M | 662.36M | 327.66M | 307.73M | 248.97M | 171.40M | 269.19M | 355.74M | 211.27M | 404.38M | 397.77M | 438.75M | 489.22M | 294.53M | 450.96M |
| Net Income | 1.25B | 1.10B | 735.35M | 1.50B | 676.68M | 783.29M | 736.68M | 465.89M | 489.60M | 605.50M | 282.98M | 572.39M | 569.04M | 490.16M | 195.04M | 129.72M | 354.82M |
| Net Income Ratio | 4.15% | 4.31% | 3.20% | 6.69% | 4.28% | 4.82% | 4.66% | 3.08% | 3.35% | 4.20% | 2.06% | 3.98% | 3.85% | 3.34% | 1.35% | 1.01% | 3.47% |
| EPS | 0.00 | 78.51 | 52.33 | 107.12 | 48.12 | 55.70 | 58.28 | 38.48 | 40.47 | 50.64 | 23.82 | 48.14 | 47.74 | 41.13 | 16.35 | 10.82 | 29.55 |
| EPS Diluted | 0.00 | 78.46 | 52.08 | 106.30 | 48.12 | 55.70 | 58.28 | 38.48 | 40.34 | 50.00 | 23.48 | 48.14 | 47.74 | 41.12 | 16.34 | 10.80 | 27.53 |
| Weighted Avg Shares Out | 0.00 | 14.04M | 14.05M | 13.96M | 14.06M | 14.06M | 12.64M | 12.11M | 12.10M | 11.96M | 11.88M | 11.89M | 11.92M | 11.92M | 11.93M | 11.99M | 12.01M |
| Weighted Avg Shares Out (Dil) | 0.00 | 14.05M | 14.12M | 14.07M | 14.06M | 14.06M | 12.64M | 12.11M | 12.14M | 12.11M | 12.05M | 11.89M | 11.92M | 11.92M | 11.94M | 12.01M | 12.89M |
Source: https://incomestatements.info
Category: Stock Reports